<scp>CD30</scp> as a Target Molecule in the Diagnosis and Therapy of Lymphomas

The tumor necrosis factor (TNF)-receptor superfamily 8 receptor CD30 molecule is expressed in all tumor cells of Hodgkin lymphoma and anaplastic large cell lymphoma but is only weakly expressed in a small subset of large lymphoid cells in normal peripheral lymphoid tissues. This makes this molecule an important target for the diagnosis and treatment of CD30-expressing lymphomas. We describe the road to the discovery of the CD30 molecule and the way CD30 has contributed to more precise diagnosis and classification of lymphomas. Moreover, we address how anti-CD30 immunotherapy was developed and the impact of the anti-CD30-auristatin conjugate and anti-CD30 CAR-T cells in treating CD30-expressing lymphomas.

Authors

Institutions

Publication Details

Journal
American Journal of Hematology
Published
2025-10-22
DOI
https://doi.org/10.1002/ajh.70107
Citations
1
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
1.05
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

CD30 as a Target Molecule in the Diagnosis and Therapy of Lymphomas

Brunangelo Falini, Harald Stein
1 citations
American Journal of Hematology
CAR-T cell therapy research
1.05
article

CD30 as a Target Molecule in the Diagnosis and Therapy of Lymphomas

Brunangelo Falini, Harald Stein
article en
1 citations

Abstract

The tumor necrosis factor (TNF)-receptor superfamily 8 receptor CD30 molecule is expressed in all tumor cells of Hodgkin lymphoma and anaplastic large cell lymphoma but is only weakly expressed in a small subset of large lymphoid cells in normal peripheral lymphoid tissues. This makes this molecule an important target for the diagnosis and treatment of CD30-expressing lymphomas. We describe the road to the discovery of the CD30 molecule and the way CD30 has contributed to more precise diagnosis and classification of lymphomas. Moreover, we address how anti-CD30 immunotherapy was developed and the impact of the anti-CD30-auristatin conjugate and anti-CD30 CAR-T cells in treating CD30-expressing lymphomas.

American Journal of HematologyVol. 101(1)
University of Perugia (IT), Azienda Ospedaliera di Perugia (IT), Pathodiagnostik Berlin (DE)
Openalex Percentile: Top 17%
CAR-T cell therapy research
1.05
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

<scp>CD30</scp> as a Target Molecule in the Diagnosis and Therapy of Lymphomas — Brunangelo Falini, Harald Stein · American Journal of Hematology (2025) | TGRS Research Map | TGRS